Noiafren (Clobazam)

Clobazam enhances the activity of the neurotransmitter GABA by binding to a specific site on the GABA‑A receptor complex. This positive allosteric modulation increases chloride ion flow into neurons, hyperpolarising them and reducing neuronal excitability, which contributes to its anticonvulsant effect.

The dosage of Noiafren is individualized. A qualified prescriber determines the appropriate dose based on the patient’s age, weight, seizure type, response to other antiepileptic drugs, and overall clinical condition. Patients should follow the prescribing information provided by their healthcare professional.

Clobazam is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be used during pregnancy only if the potential benefit justifies the risk. Limited data are available for breastfeeding; therefore, a healthcare provider should evaluate the risk‑benefit ratio before use.

To request Noiafren, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Clobazam belongs to the benzodiazepine class, offering rapid enhancement of GABA‑mediated inhibition. Compared with non‑benzodiazepine anticonvulsants, it may provide quicker seizure control but carries a higher potential for sedation, dependence and withdrawal. Selection depends on the patient’s seizure profile, comorbidities and tolerance for side‑effects.

Noiafren should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Noiafren is taken orally, usually as a tablet. It is swallowed whole with water and can be taken with or without food, as directed by the prescribing clinician. The exact timing and frequency are determined by the treating physician.

Serious risks include respiratory depression, especially when combined with other CNS depressants, severe skin reactions such as Stevens‑Johnson syndrome, and the potential for dependence or withdrawal seizures if the medication is stopped abruptly. Patients should be monitored closely for these events.

Noiafren is contraindicated in individuals with known hypersensitivity to clobazam or other benzodiazepines, patients with severe respiratory insufficiency, and those taking potent CYP3A4 inhibitors that could markedly increase drug levels. Pregnant women should only use it when clearly needed, and it should be avoided in patients with a history of severe drug dependence.